The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KRAS mutations as predictive biomarker in patients with EGFR wild-type stage IV nonsquamous non-small cell lung cancer (NSCLC) recruited in a phase II clinical study with carboplatin-docetaxel-bevacizumab.
Manuel Domine
No relevant relationships to disclose
Yann Izarzugaza
No relevant relationships to disclose
Federico Rojo
No relevant relationships to disclose
Francisco Lobo
No relevant relationships to disclose
Maria Jesus Fernandez-Acenero
No relevant relationships to disclose
Victoria Casado
No relevant relationships to disclose
Gustavo Rubio
No relevant relationships to disclose
Juan Luis Arranz
No relevant relationships to disclose
Ana Leon
No relevant relationships to disclose
Jose Ignacio Martin-Valades
No relevant relationships to disclose
Gloria Serrano
No relevant relationships to disclose
Cristina Carames
No relevant relationships to disclose
Sharon Cordova
No relevant relationships to disclose
Juan Madoz
No relevant relationships to disclose
Sandra Zazo
No relevant relationships to disclose
Raul Rincon
No relevant relationships to disclose
Carmen Canadas
No relevant relationships to disclose
Angel Campos
No relevant relationships to disclose
Nuria Perez-Gonzalez
No relevant relationships to disclose
Jesus Garcia-Foncillas
No relevant relationships to disclose